Strategy's stock plunged in 2025 after achieving significant gains in the previous year. Fundamentally, there's not much of a reason to invest in the company as its top line has been declining.

In 2005, physicists David Frame and Myles Allen were on their way to a scientific conference in Exeter, UK, and had been, in Frame’s words, “fiddling about” with a climate model to prepare for their ...

Why We Upgraded This Fidelity Large-Growth Fund to Gold ...

For the first time in decades, net migration for the United States was likely negative in 2025, and the trend could continue amid President Donald Trump's aggressive immigration enforcement actions, ...

For the first time in at least half a century, more immigrants left the United States than entered last year, according to new estimates released Tuesday by economists at the Brookings Institution.

Will Christian McCaffrey and George Kittle be difference-makers in postseason fantasy football formats? Mike Christy / Getty Images The normal fantasy football regular season might be over, but the ...

Michael Saylor has long noted that Bitcoin’s volatility “is a feature, not a bug” when pitching his cryptocurrency accumulator Strategy Inc. Investors will soon see the downside of that, with the ...

CSIR NET Answer Key 2025: The National Testing Agency (NTA) has officially released the CSIR NET Answer Key 2025 on December 30, 2025 at csirnet.nta.ac.in. Candidates who appeared for the Joint ...

In 2025, the edges of mathematics came a little more sharply into view when members of the online Busy Beaver Challenge community closed in on a huge number that threatens to defy the logical ...

Bitcoiners wanting to focus on short-term factors should be “fairly methodical and mathematical,” says Strategy CEO Phong Le. Bitcoin’s market fundamentals have stayed strong in 2025, despite the ...

Tesla Inc. (NASDAQ: TSLA) CEO Elon Musk’s net worth is up sharply this year to at least $647 billion. There is speculation that his net worth could top $1 trillion. Follow 24/7 Wall St. on Google By ...

In 2025, my biotech-focused portfolio delivered a 34.3% average return, outperforming the S&P 500 by 20.6%. I prioritize small- and mid-cap biotechs with FDA-approved drugs entering commercialization, ...